Baolingbao Biology Co.,Ltd. (SHE:002286)

Market Cap	3.63B
Revenue (ttm)	2.62B
Net Income (ttm)	134.50M
Shares Out	380.12M
EPS (ttm)	0.36
PE Ratio	26.54
Forward PE	20.56
Dividend	0.12 (1.26%)
Ex-Dividend Date	Jul 3, 2025

Volume	13,577,747
Average Volume	14,317,854
Open	9.56
Previous Close	9.56
Day's Range	9.27 - 10.06
52-Week Range	5.91 - 13.40
Beta	0.42
RSI	27.64
Earnings Date	Oct 28, 2025

About Baolingbao Biology

Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and maltose; dietary fiber products comprising polydextrose and resistant dextrin; modified, waxy maize, and corn starch products; starch sugar products, incl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,395
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002286

Financial Performance

In 2024, Baolingbao Biology's revenue was 2.40 billion, a decrease of -4.84% compared to the previous year's 2.52 billion. Earnings were 111.16 million, an increase of 105.97%.